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 Risks, Benefits and DTC – An Analysis of Information Formats  
 
Janet Hoek, Philip Gendall, Massey University,  





Critics of direct to consumer prescription medicine advertising (DTC) claim it is unbalanced 
because benefit information features more prominently than risk information, and that it thus 
fails to meet the high standards of social responsibility called for in regulatory codes.  We used 
respondent conditioning theory to examine whether variations in risk information format could 
improve recall of benefits, side effects and contra-indications in print DTC advertisements. A 
best-worst study confirmed striking differences in preference for varied information formats, 
while a second study found that visual heuristics increased recall of both risk and benefit 
information. The findings question marketers’ reluctance to provide easily accessible risk 
information and suggest prominent drug information panels may discharge manufacturers’ social 





Proponents of prescription medicine advertising (DTC) claim it provides important benefits 
including more informed discussions with doctors, speedier diagnoses, better compliance with 
treatment regimes and improved reach to groups that may have difficulty accessing health 
information (Burak & Damico, 1999; Calfee, 2002; Kelly, 2004; Donohue, 2006; Bradford & 
Kleit, 2006; Lee et al, 2007).  However, others have questioned whether awareness of a drug’s 
indications implies potential users are knowledgeable about other attributes, such as its risks 
(Hoffman & Wilkes, 1999; Mintzes et al, 2002; Toop et al, 2003; Huh and Cude, 2004). Morris 
et al (1985) found consumers did not always understand risk details and were more likely to 
ascribe benefits than risks to promoted drugs (Basara, 1992; Davis, 2000; Kopp & Bang, 2000).  
 
DTC promotions emphasise benefit information, which is expressed in simple language, has 
greater visual prominence, and thus may be more salient to consumers (Adams & Edworthy 
1995). By contrast, risk information is often technical, shown in a small font, and confined to a 
small section of an advertisement. As Pitts noted: “Risk information is hidden in plain view and 
benefits are communicated broadly” (2004, p.260). A recent FDA survey reported that half the 
respondents found DTC hard to read, while 60% thought it did not contain enough risk 
information (Aitken et al, 2004).  Researchers from New Zealand, the only other nation to allow 
DTC, have reported similar conclusions; for example, Hoek, Gendall and Calfee (2004) found 
that over 80% of consumers believe DTC is skewed in favour of benefit information.    
 
These findings raise important questions about how risk information is communicated to 
potential users. Stewart and Martin (1994), among others, examined warning labels, which have 
many similarities to risk information panels, and concluded that consumers’ responses to these 
depend on their demographic traits, knowledge and experience (see also Petty et al, 1983; 
 Friedmann, 1988; Kavadas et al, 2007; Lee et al, 2007). Argo & Main’s (2004) meta-analysis of 
warning information found that mechanical features affect the cognitive demands placed on 
consumers. Advertising researchers have drawn on ergonomics research examining how 
different colours and font sizes minimise consumers’ interpretive burden (Bettman et al 1987; 
Laughery et al,1993; Braun and Silver, 1995; Wogalter & Shaver, 2001; Wogalter et al, 2002).   
 
Although parallel studies have explored how consumers interpret warnings (Burton & Andrews, 
1996; Andrews et al, 1991; 1998), these have focussed on warning content, not format, and 
inevitably conclude by calling for research into format variations. As DTC contains mandatory 
information that cannot be changed, research examining the formatting of visual stimuli is 
timely. Behaviour modification theory (BMT), particularly respondent conditioning, provides a 
framework for hypothesising how learned associations evoked by visual stimuli affect responses 
to risk information. BMT focuses on external stimuli, the conditioned responses these elicit, and 
the resulting reduction in cognitive processing required of consumers.  Nord and Peter (1980) 
argued that the resulting associations may become so strongly paired they eventually function as 
heuristics, or discriminative stimuli, that simplify cognitive tasks by activating previously 
experienced contexts (Bettman et al, 1998).   
 
Tests of heuristics’ effects have examined several variables; of these, recall is the most relevant 
to DTC, since its primary purpose is to convey information that will activate the information 
processing pathway. As Roth (2003) stated: “… generating advertising recall is the first critical 
marketing communication objective for a balanced DTC drug advertisement” (p. 181). Recall is 
widely used as a measure of advertising effectiveness and estimates consumers’ ability to 
retrieve information provided by a stimulus, such as a print advertisement (Zinkhan, 1982). 
Because DTC informs subsequent decisions, recall of relevant risk information promotes 
effective healthcare management; furthermore, higher risk recall is positively correlated with 
warning compliance (Hilton,1993; Laughery et al 1993).  
 
As colour and increases in font size are associated with increased recall of risk information 
(Laughery et al, 1993; Adams & Edworthy, 1995; Wogalter et al, 2002), we posited that these 
variables would enhance the communication effectiveness of a DTC advertisement.  Risk 
information in New Zealand DTC appears in a small paragraph, however, as Wogalter and 
Shaver (2001) found outline formats that grouped details improved recall, we tested whether use 
of an outline format enhanced the perceived communication effectiveness of the advertisement.  
The BMT suggests heuristics simplify the assimilation of detailed information and we also 
explored the effect a conditioned visual cue, namely a “traffic light” heuristic, had on perceived 
communication effectiveness and attribute recall.  Since benefit information appears in 
advertising copy, headlines and visuals as well as the information panel, we surmised that 




We developed a DTC advertisement for a fictitious allergy drug, Nasolin, which relieved 
symptoms of congestion, sneezing and itchy, runny nose. Results from formative evaluation 
using depth interviews informed refinement of the six information panels used in two subsequent 
studies.  The first panel represented the status quo and thus functioned as a control; it used a 
 paragraph format with 10 point text while the second panel used a coloured background to 
increase its visual prominence.  The third and fourth panels used 12 point (rather than 10 point) 
font. The final panels used 12 point font and presented the information in an outline format that 
grouped details into symptom (or benefit), side effect, and risk columns; one version was 
uncoloured while the other drew on a “traffic light” heuristic by using green, orange and red 
colours, in the benefit, side effect and risk panels, respectively.   
 
A Best Worst Scaling (BWS) experiment was used to test the hypothesised pattern of 
information accessibility and preferences for the different formats. Developed by Finn and 
Louviere (1992) as an alternative to discrete choice experiments, BWS requires respondents to 
evaluate and compare the utilities of different attribute levels presented to them, then select both 
the best (highest utility) and the worst (lowest utility) option from the choices viewed. BWS 
assumes respondents select the pair of options that differ most on an underlying subjective 
dimension, such as “degree of preference” (Auger, Devinney and Louviere, 2004). BWS avoids 
problems associated with rating scales and ranking question, which often produce tied items, and 
enables ratio-scaled comparisons between the attributes estimated (Flynn et al, 2006).   
 
A balanced incomplete block design (BIBD) using 10 showcards was developed and mall 
intercept interviews were conducted with a systematically selected sample of 170 respondents.  
Each respondent was asked to identify the format that was most effective (best) and least 
effective (worst) at communicating information about Nasolin; other questions explored whether 
respondents or their families suffered from allergies.  The sample had a broad demographic 
profile; 71% were personally affected by an allergy or had a close family member who suffered 
from allergies. There were no differences in the proportion of respondents affected by allergies 
across any of the demographic variables.  
 
The second study used three formats that varied widely in perceived communication 
effectiveness. Data were collected via 300 mall intercept interviews, using the same systematic 
selection procedures as the BWS experiment. Respondents had 30 seconds to peruse an 
advertisement featuring one of the three information panels before being tested on their 
(unaided) recall of the advertisement content. Pre-coded open-ended recall questions examined 
respondents’ knowledge of the brand name, symptoms, risks, side effects, contra-indications and 
usage instructions. The questionnaire included the same demographic and allergy questions used 
in the BWS survey.  There were no significant differences in respondents’ gender, education or 





We had hypothesised that introducing colour would improve perceptions of a format’s 
communication effectiveness and that a larger font size (from 10 point to 12 point) would further 
enhance these perceptions.  Finally, we surmised that dividing the information into logical 
segments would improve a format’s perceived communication effectiveness, and that a colour 
heuristic (the traffic light shading) would be perceived as more effective again.  Table 1 contains 
the results relating to these hypotheses. 
 
 Table 1: BWS Estimates of Perceived Communication Effectiveness  





Paragraph (control) -624 -0.73  
Paragraph with colour -483 -0.57 Colour = .13 
Paragraph with larger font -65 -0.08  
Paragraph with larger font 
and colour 14 0.02 
 
Font size = .62 
Outline format (larger font) 434 0.51 Outline format = .59 
Outline format – traffic light 
(larger font) 720 0.85 
 
Three colour = .34 
1.   The first column contains the sum of the best scores minus the worst scores, the second uses the best-worst 
score to calculate a standardised score where: 
Standard Score =   Count best – Count worst 
    _____________________ 
          5n 
n is the number of questionnaires and 5 is the frequency with which each option appears in the experimental design 
(Goodwin et al, 2005). The standardised scores are conceptually equivalent to standardised regression coefficients 
with the signs taken into account and indicate the relative perceived effectiveness of the information formats tested. 
 
The paragraph option was the least effective format, and a background colour only slightly 
increased its perceived effectiveness. However, increased font size, an outline format, and 
“traffic light” colour coding, all produced higher preference scores. The BWS results showed an 
additive effect across the formatting devices, supported our hypotheses, and functioned as a 
manipulation check that confirmed respondents saw the formats tested as very different.  
  
The second study used the control, outline and traffic light formats and examined whether 
consumers’ ability to recall information varied according to the format they saw. MANOVA was 
used to test differences in respondents’ recall of benefits and risks; Table 2 contains these results.   
 










Symptoms Treated (Benefits) 
Sneezing 60 55 65 ns 
Runny itchy nose 46 53 671 .00 
Congestion 26 20 26   ns 
None recalled 6 7 3   ns 
Mean recall 1.3 1.3 1.61 .01 
Side Effects (Mild Risks) 
Headache 21 26 32   ns 
Nosebleed 18 19 18   ns 
Sore throat 7 10 8   ns 
Nose infection 4 10 221 .00 
 None recalled 66 57 55  ns 
Mean risk recall .53 .6 .82 .04 
Contra-indications (Serious Risks)  
MAO inhibitors 20 421 371 .00 
Age < 4 18 311 351 .03 
High blood pressure 12 16 431 .00 
Urine retention 6 221 341 .00 
None recalled 511 17 17 .00 
Mean recall .7 1.41 1.71 .00 
1. Estimate significantly higher than unmarked estimates (p<.05). 
2. Estimate significantly higher than estimate marked 3 (p<.05). 
 
We hypothesised that respondents’ recall of the product benefits would not vary; for two of the 
three symptoms, no differences were detected. However, respondents who saw the “traffic light” 
stimulus were more likely to mention runny nose symptoms and recalled a significantly higher 
mean number of product indications than respondents exposed to the other versions. People who 
saw the control recalled fewer side effects than those who saw an outline format, and a higher 
proportion of the former recalled no side effects. Mean side effect recall following exposure to 
the “traffic light” format was significantly higher than the control.  Respondents who saw an 
outline format recalled significantly more contra-indications; half those exposed to the control 
recalled no contra-indications. Table 2 suggests increased font size combined with an outline 
format improved recall of both mild and serious side effects, as did the “traffic light” heuristic. 
The final hypothesis, that benefit recall would not differ, was only weakly supported; this implies 
that presenting risk information in a more visually salient format does not detract from benefits.  
 
 
Discussion and Conclusions 
 
Research that examines whether risk information could go beyond merely satisfying regulatory 
requirements has important health implications. The new formats tested rated more highly on 
perceived effectiveness and significantly increased recall of serious risk details and, to a lesser 
extent, recall of symptom (benefit) and side effect information.  Although we hypothesised that 
recall of symptom details would not vary across the formats, since it is not confined to the 
information panel, symptom recall increased in response to larger font size, an outline format and 
a colour heuristic. This implies that advertisers should not resist calls to increase the space 
allocated to information panels, since larger and more accessible panels appear to increase recall 
of product indications, and may promote related behaviours, such as further information search.  
 
Replications and extensions are required to test other formatting variations, repeated exposure 
measures, and whether our findings are generalisable to other drug categories, particularly those 
with different risk and user profiles. However, if risk information in DTC is to be functionally as 
well as physically present, our findings suggest changes to its presentation are essential.  By 
integrating findings from warning label research with respondent conditioning theory, we have 
identified formats that significantly increased recall of serious risk information.  Adoption of the 
formats found to be effective would improve consumers’ ability to access information, assist 
their decision to seek further advice, and may even help them avoid serious health complications. 
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